Nexalin Technology Inc. has announced a partnership with the University of California, San Diego (UCSD) to launch NeuroCare®, an AI-driven virtual clinic platform. This collaboration integrates Nexalin's Gen-3 HALO™ neurostimulation headset with the NeuroCare digital platform, enabling remote, physician-monitored neurotherapy for conditions such as Alzheimer's, mood disorders, traumatic brain injury $(TBI)$, and PTSD. The initiative aims to increase patient access, reduce costs, and support long-term care through a subscription-based model, leveraging UCSD's clinical research infrastructure for initial deployment and ongoing clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649358-en) on February 05, 2026, and is solely responsible for the information contained therein.